These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 28868993)

  • 21. Use of Patient Preferences in Health Technology Assessment: Perspectives of Canadian, Belgian and German HTA Representatives.
    van Overbeeke E; Forrester V; Simoens S; Huys I
    Patient; 2021 Jan; 14(1):119-128. PubMed ID: 32856278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recommendations for the Implementation of Hospital Based HTA in Poland: Lessons Learned From International Experience.
    Gałązka-Sobotka M; Kowalska-Bobko I; Lach K; Mela A; Furman M; Lipska I
    Front Pharmacol; 2020; 11():594644. PubMed ID: 34054508
    [No Abstract]   [Full Text] [Related]  

  • 23. Early Health Technology Assessment during Nonalcoholic Steatohepatitis Drug Development: A Two-Round, Cross-Country, Multicriteria Decision Analysis.
    Angelis A; Thursz M; Ratziu V; O'Brien A; Serfaty L; Canbay A; Schiefke I; Costa JBE; Lecomte P; Kanavos P
    Med Decis Making; 2020 Aug; 40(6):830-845. PubMed ID: 32845234
    [No Abstract]   [Full Text] [Related]  

  • 24. Acceptability of Using Real-World Data to Estimate Relative Treatment Effects in Health Technology Assessments: Barriers and Future Steps.
    Gomes M; Turner AJ; Sammon C; Dawoud D; Ramagopalan S; Simpson A; Siebert U
    Value Health; 2024 May; 27(5):623-632. PubMed ID: 38369282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Conducting a health technology assessment in the West Bank, occupied Palestinian territory: lessons from a feasibility project.
    Isbeih M; Heupink LF; Qaddomi S; Salman R; Chola L
    Int J Technol Assess Health Care; 2024 Feb; 40(1):e12. PubMed ID: 38357734
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Challenges of palliative care identified by stakeholders in resource-limited settings: A multi-regional study in Kazakhstan.
    Salikhanov I; Yuliya S; Aceti M; Schweighoffer R; Kunirova G; Khashagulgova F; Crape BL; Katapodi MC
    J Cancer Policy; 2024 Jun; 40():100474. PubMed ID: 38513969
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective.
    Quinn C; Garrison LP; Pownell AK; Atkins MB; de Pouvourville G; Harrington K; Ascierto PA; McEwan P; Wagner S; Borrill J; Wu E
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32661115
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ethical, legal, and social issues in health technology assessment for prenatal/preconceptional and newborn screening: a workshop report.
    Potter BK; Avard D; Entwistle V; Kennedy C; Chakraborty P; McGuire M; Wilson BJ
    Public Health Genomics; 2009; 12(1):4-10. PubMed ID: 19023190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Opportunities and Challenges in Cross-Country Collaboration: Insights from the Beneluxa Initiative.
    Claessens Z; Lammens M; Barbier L; Huys I
    J Mark Access Health Policy; 2024 Sep; 12(3):144-157. PubMed ID: 39072305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Palliative care national plan implementation through stakeholder analysis.
    Antonio Sánchez-Cárdenas M; Ximena León-Delgado M; María Vargas-Escobar L; Elizabeth Muñoz Medina S; Milena Buitrago Florian P; Andrade Fonseca D; Esteban Correa-Morales J
    BMC Palliat Care; 2024 Jul; 23(1):163. PubMed ID: 38951852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Putting Stakeholder Engagement at the Center of Health Economic Modeling for Health Technology Assessment in the United States.
    Xie RZ; Malik ED; Linthicum MT; Bright JL
    Pharmacoeconomics; 2021 Jun; 39(6):631-638. PubMed ID: 33982198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Community stakeholder preferences for evidence-based practice implementation strategies in behavioral health: a best-worst scaling choice experiment.
    Williams NJ; Candon M; Stewart RE; Byeon YV; Bewtra M; Buttenheim AM; Zentgraf K; Comeau C; Shoyinka S; Beidas RS
    BMC Psychiatry; 2021 Feb; 21(1):74. PubMed ID: 33541301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overcoming Barriers in Hospital-Based Health Technology Assessment (HB-HTA): International Expert Panel Consensus.
    Lipska I; Di Bidino R; Niewada M; Nemeth B; Bochenek T; Kukla M; Więckowska B; Sobczak A; Iłowiecka K; Zemplenyi A; Martelli N; Martin T; Filiniuk O; Kosyachenko K; Sucu R; Piniazhko O; Zaliska O; Avdeyev A; Shanazarov N; von Pinoci M; Hren R
    Healthcare (Basel); 2024 Apr; 12(9):. PubMed ID: 38727447
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experiences of patient organizations' involvement in medicine appraisal and reimbursement processes in Finland - a qualitative study.
    Tran Minh M; Airaksinen M; Lahti T
    Int J Technol Assess Health Care; 2024 Jul; 40(1):e26. PubMed ID: 38953740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies - can alignment be improved?
    Wolters S; de Jong LA; Jansen C; Jansman FG; Postma MJ
    Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):251-265. PubMed ID: 37747280
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Guidance from key organisations on exploring, confirming and interpreting subgroup effects of medical treatments: a scoping review.
    Wijn SRW; Rovers MM; Le LH; Belias M; Hoogland J; IntHout J; Debray T; Reitsma JB
    BMJ Open; 2019 Aug; 9(8):e028751. PubMed ID: 31446407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Successful implementation of a stakeholder engagement program for pharmacoepidemiologic research.
    Cromer SJ; Steiner B; York C; Mastrorilli J; Lake GA; Leibowitz S; Simmons L; Steppel-Reznik J; Low G; Fischer MA; Patorno E; Wexler DJ
    Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5727. PubMed ID: 37985010
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Implicit factors influencing the HTA deliberative processes in 5 European countries: results from a mixed-methods research.
    Monleón C; Martin-Späth H; Crespo C; Dussart C; Toumi M
    Health Policy Open; 2023 Dec; 5():100109. PubMed ID: 38073709
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How health technology assessment can help to address challenges in drug repurposing: a conceptual framework.
    Abu-Zahra T; Grimm SE; Scholte M; Raymakers AJN; Kesselheim AS; Joore M
    Drug Discov Today; 2024 Jun; 29(6):104008. PubMed ID: 38692506
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Avoiding health technology assessment: a global survey of reasons for not using health technology assessment in decision making.
    Teerawattananon Y; Painter C; Dabak S; Ottersen T; Gopinathan U; Chola L; Chalkidou K; Culyer AJ
    Cost Eff Resour Alloc; 2021 Sep; 19(1):62. PubMed ID: 34551780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.